SCHEDULE 13G/A 0001172661-25-005271 0001281446 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 12/31/2025 0001817229 VOR BIOPHARMA INC. 929033207 500 Boylston Street Suite 1350 Boston MA 02116 Rule 13d-1(c) Great Point Partners, LLC DE 0.00 1370107.00 0.00 1370107.00 1370107.00 N 3.30 IA OO Dr. Jeffrey R. Jay, M.D. X1 0.00 1370107.00 0.00 1370107.00 1370107.00 N 3.30 HC IN Ms. Lillian Nordahl X1 0.00 1370107.00 0.00 1370107.00 1370107.00 N 3.30 HC IN VOR BIOPHARMA INC. 500 BOYLSTON STREET, SUITE 1350, BOSTON, MA, 02116 Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl The Reporting Persons have entered into a Joint Filing Agreement, dated February 17, 2026, a copy of which is filed with this SCHEDULE 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830 Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States. Y 1,370,107.00 3.30% 0 1,370,107.00 0 1,370,107.00 The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 41,519,840 shares outstanding, as reported by the Issuer in its Form S-3 registration statement as filed with the Securities and Exchange Commission (the "SEC") on January 29, 2026. N Y N See Item 4. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl Great Point Partners, LLC /s/ Dr. Jeffrey R. Jay, M.D 02/17/2026 Dr. Jeffrey R. Jay, M.D. /s/ Dr. Jeffrey R. Jay, M.D 02/17/2026 Ms. Lillian Nordahl /s/ Ms. Lillian Nordahl 02/17/2026